The 12th World Congress on Controversies in Multiple Myeloma (COMy 2026), held in Paris, France, brought together leading hematologists and myeloma specialists from around the world to discuss the future of multiple myeloma treatment.
One of the dominant themes throughout the conference was the rapidly expanding role of CAR-T therapy for multiple myeloma. Experts presented new data showing how advanced cellular therapies are changing outcomes for patients with relapsed and refractory myeloma, including patients who previously had very limited treatment options.
Several sessions focused on:
- CAR-T therapies targeting BCMA, including cilta-cel and ide-cel
- Earlier use of CAR-T therapy in the treatment line
- Managing relapse after CAR-T
- New-generation dual-target CAR-T approaches
- Combination strategies with bispecific antibodies and immunotherapy
- Long-term remission and MRD-negative responses after CAR-T treatment
The conference repeatedly addressed an important question many patients ask today: “What is the new treatment for myeloma in 2026?” According to many presentations at COMy 2026, the answer increasingly includes advanced immunotherapy approaches such as CAR-T therapy and bispecific antibodies, which are transforming the treatment landscape of multiple myeloma.
In addition to CAR-T therapy, the congress also explored:
- Advanced treatments for myeloma using bispecific antibodies
- Personalized medicine approaches
- Treatment sequencing after relapse
- Earlier intervention in high-risk patients
- Research into achieving durable remission and potential functional cure
There was considerable participation by physicians from Sheba Medical Center, reflecting the hospital’s ongoing involvement in international hematology and cellular therapy research. Among the participating physicians was Dr. Arnon Nagler, one of Israel’s leading hematologists and transplant specialists, who served as one of the congress chairs alongside Prof. Mohamad Mohty and Prof. María-Victoria Mateos.
Photo credit: Comy Congress
Dr. Nagler participated in multiple scientific discussions during the congress, particularly in areas related to advanced immunotherapy, CAR-T therapy, bone marrow transplantation, and relapsed/refractory multiple myeloma. He has long been involved in international myeloma and cellular therapy research and is recognized for his contribution to the field of hematology and stem cell transplantation.
The overall atmosphere at COMy 2026 was optimistic. While multiple myeloma remains a complex disease, the rapid development of CAR-T therapy and other advanced myeloma treatments is creating new possibilities for patients around the world.
Publication date: May 2026
